A Pancreatic Cancer Drug Shrank Lung Tumors in an Early Trial, but Four Patients Died from Adverse Events

Daraxonrasib shrank tumors in RAS-mutant lung cancer in an early trial, but most patients had side effects, and four died.

Have A Referral?